搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Max Planck Society
4 小时
Cancer therapy with protein design
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
cancerhealth
3 天
Engineered Receptors Help the Immune System Home in on Cancer
Researchers developed synthetic receptors on the surface of immune cells that could make cancer immunotherapies more targeted.
3 天
on MSN
Putting the brakes on prostate cancer cells: Androgen receptor can alter normal prostate growth
Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to ...
1 天
Once-a-day breast cancer tablet to be rolled out on NHS
A once-a-day tablet for advanced breast cancer will be rolled out on the NHS. More than 1,000 women will be eligible for the ...
腾讯网
4 天
NEJM:一次注入162亿免疫细胞,肿瘤病灶消失72%,神奇的TCR-T细胞疗法
近日,NEJM上发表的一种新型免疫疗法TCR-T疗法引起轰动!原文题目为“Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer”。一位转移性胰腺癌晚期患者(KRAS ...
3 天
on MSN
Images of crucial cell receptors show promising new drug targets
New research from the University of Chicago combines two powerful imaging techniques to study the complete structure of a ...
Cure Today
1 天
Targeting Multiple Pathways Improves Outcomes in Some With Metastatic Breast Cancer
Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...
EurekAlert!
5 天
Treating prostate cancer with novel platinum complex via targeting androgen receptor signaling
Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat.
Medscape
1 天
T-DXd Shows Consistent Benefit Across Endocrine-Resistant HR+/HER2-Low Breast Cancer Subgroups
New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...
Medscape
21 小时
HRQOL the Same With CDK4/6 Inhibitors in 1st or 2nd Line in Breast Cancer
An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈